Future oncology最新文献_第9页

QuANTUM-Wild: a Phase III, randomized trial of quizartinib in newly diagnosed FLT3-ITD-negative acute myeloid leukemia. QuANTUM-Wild: quizartinib治疗新诊断的flt3 - itd阴性急性髓性白血病的III期随机试验

IF 3.1 4区医学

Future oncology Pub Date : 2026-07-01 Epub Date: 2026-07-11 DOI: 10.1080/14796694.2026.2689464

Pau Montesinos, Jessica K Altman, Lars Bullinger, June-Won Cheong, Amir T Fathi, Mark J Levis, Selina Luger, Toshihiro Miyamoto, Esther Natalie Oliva, Alexander E Perl, Christian Récher, Rebeca Rodriquez Veiga, Jianxiang Wang, Amer M Zeidan, Li Liu, Yvonne Duong, Jaime E Connolly Rohrbach, Giorgio Inghirami, Karenza Alexis, Andreas Gosberg, Akash Nahar, Kristy Burns, Naval Daver, Harry P Erba

{"title":"QuANTUM-Wild: a Phase III, randomized trial of quizartinib in newly diagnosed FLT3-ITD-negative acute myeloid leukemia.","authors":"Pau Montesinos, Jessica K Altman, Lars Bullinger, June-Won Cheong, Amir T Fathi, Mark J Levis, Selina Luger, Toshihiro Miyamoto, Esther Natalie Oliva, Alexander E Perl, Christian Récher, Rebeca Rodriquez Veiga, Jianxiang Wang, Amer M Zeidan, Li Liu, Yvonne Duong, Jaime E Connolly Rohrbach, Giorgio Inghirami, Karenza Alexis, Andreas Gosberg, Akash Nahar, Kristy Burns, Naval Daver, Harry P Erba","doi":"10.1080/14796694.2026.2689464","DOIUrl":"10.1080/14796694.2026.2689464","url":null,"abstract":"Quizartinib is a potent type II inhibitor of FMS-like tyrosine kinase 3 (FLT3) that demonstrated significant survival benefit among patients with newly diagnosed (ND) acute myeloid leukemia (AML) without FLT3-internal tandem duplication (FLT3-ITD) in the randomized, Phase II QUIWI trial. Here, we present the rationale and design of QuANTUM-Wild, a double-blind, randomized, placebo-controlled, Phase III study to confirm the efficacy and safety of quizartinib plus standard induction and consolidation chemotherapy and as maintenance monotherapy in adult patients with ND FLT3-ITD-negative AML. Eligible patients are randomized 2:2:1 to one of three treatment arms. Patients in Arm A (n ≈ 280) receive quizartinib plus chemotherapy during induction and consolidation (with option for transplant without study drug), followed by up to 36 cycles of single-agent maintenance therapy. Patients in Arm B (n ≈ 280) receive placebo in all treatment phases plus chemotherapy, then as maintenance monotherapy. Patients in Arm C (n ≈ 140) receive quizartinib plus chemotherapy in the induction and consolidation phases, then placebo during the maintenance phase, to specifically assess the utility of quizartinib maintenance. The primary endpoint is overall survival. Secondary endpoints include event-free survival, remission rate, and safety.Clinical trial registration: http://www.clinicaltrials.gov identifier is NCT06578247.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1913-1924"},"PeriodicalIF":3.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13390524/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148420611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Study of brentuximab vedotin combination treatment in people with early-stage Hodgkin lymphoma: a plain language summary. brentuximab vedotin联合治疗早期霍奇金淋巴瘤的研究：一个简单的语言总结。

IF 3.1 4区医学

Future oncology Pub Date : 2026-07-01 Epub Date: 2026-07-06 DOI: 10.1080/14796694.2026.2693614

Jeremy S Abramson, David J Straus, Nancy L Bartlett, John M Burke, Ryan C Lynch, Eva Domingo Domenech, Brian Hess, Steven R Schuster, Yuliya Linhares, Mitul Gandhi, Harsh R Shah, Wojciech Jurczak, Alessandro Re, Uwe Hahn, H Miles Prince, Wenchuan Guo, Griffith Davis, Linda Ho, Michelle Fanale, Christopher A Yasenchak, Hun Ju Lee

引用次数: 0

Time-to-progression ratio as a potential study endpoint in early-phase oncology trials: pooled analysis of phase II trials from the Australian MoST program. 时间进展比作为早期肿瘤试验的潜在研究终点：来自澳大利亚MoST项目的II期试验的汇总分析

IF 3.1 4区医学

Future oncology Pub Date : 2026-07-01 Epub Date: 2026-06-16 DOI: 10.1080/14796694.2026.2688570

Derrick H W Siu, Frank P Y Lin, David M Thomas, Subotheni Thavaneswaran, David Espinoza, Sarah Chinchen, Mandy L Ballinger, R John Simes, Chee Khoon Lee

{"title":"Time-to-progression ratio as a potential study endpoint in early-phase oncology trials: pooled analysis of phase II trials from the Australian MoST program.","authors":"Derrick H W Siu, Frank P Y Lin, David M Thomas, Subotheni Thavaneswaran, David Espinoza, Sarah Chinchen, Mandy L Ballinger, R John Simes, Chee Khoon Lee","doi":"10.1080/14796694.2026.2688570","DOIUrl":"10.1080/14796694.2026.2688570","url":null,"abstract":"Purpose: Time-to-progression ratio (TTPr) measures intra-patient treatment benefit by comparing disease control on study treatment with that of the immediately preceding therapy. Its prognostic validity in the immune checkpoint inhibitor (ICI) era remains uncertain.Methods: We performed a pooled patient-level analysis of eight phase II trials. Associations between TTPr, TTP on prior therapy (TTP1), and on-study TTP (TTP2/ PFS), objective response rate (ORR), with overall survival (OS) were evaluated using Cox regression. Landmark analyses at 6-months were used to mitigate guarantee-time bias.Results: Among 246 evaluable participants, median TTP1 and TTP2 were 3.9 and 2.1 months, respectively, with poor correlation (r = 0.02). TTPr was not associated with OS (TTPr ≥1.3 vs <1.3, HR 0.85, 95% CI 0.57-1.26). In contrast, TTP2 and ORR were strongly prognostic (TTP2 ≥2.1 months vs <2.1 months: HR 0.51, 95% CI 0.35-0.76, p < 0.001); (response vs non-response: HR 0.19, 95% CI 0.07-0.52, p = 0.001) and remained independently associated with OS in multivariable analyses. Findings were consistent across ICI and non-ICI trials.Conclusions: TTPr is not a robust prognostic measure in platform trials. Although this raises concern regarding its validity as a surrogate endpoint for OS, formal evaluation requires randomized treatment comparisons.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1965-1974"},"PeriodicalIF":3.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13390511/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148257961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction. 修正。

IF 3.1 4区医学

Future oncology Pub Date : 2026-07-01 Epub Date: 2026-02-20 DOI: 10.1080/14796694.2026.2635169

引用次数: 0

A plain language summary of the SAVANNAH study: savolitinib plus osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification whose cancer had grown or spread on osimertinib. 萨凡纳研究的简单语言总结：savolitinib加奥西替尼治疗egfr突变的晚期非小细胞肺癌，MET过表达和/或扩增，肿瘤在奥西替尼上生长或扩散。

IF 3.1 4区医学

Future oncology Pub Date : 2026-07-01 Epub Date: 2026-07-16 DOI: 10.1080/14796694.2026.2692029

Filippo de Marinis, Tae Min Kim, Laura Bonanno, Susanna Cheng, Sang-We Kim, Marcello Tiseo, Quincy Chu, Claudia Proto, Adrian Sacher, Yung-Hung Luo, Silvia Novello, Desiree Hao, Christina Baik, Lyudmila Bazhenova, Jong Seok Lee, Byoung Chul Cho, Jacques Cadranel, Tuan Bao Diep, Giulio Metro, Prasad Narayanan, Yasuto Yoneshima, Javier de Castro Carpeño, Clarissa Baldotto, James Chih-Hsin Yang, Lecia V Sequist, Benjamin Levy, Ryan Hartmaier, Ike Igwegbe, Lynne Poole, Wanning Xu, Myung-Ju Ahn

引用次数: 0

Physician perspectives on the decision-making process for patients with high-risk early-stage triple-negative breast cancer in a community oncology setting. 医生对社区肿瘤学环境中高危早期三阴性乳腺癌患者决策过程的看法

IF 3.1 4区医学

Future oncology Pub Date : 2026-07-01 Epub Date: 2026-07-03 DOI: 10.1080/14796694.2026.2693604

Amin Haiderali, Linda A Okoth, Srinivas Annavarapu, Jessica K Paulus, Wilbur Pan, Paul Conkling, Michael Danso

{"title":"Physician perspectives on the decision-making process for patients with high-risk early-stage triple-negative breast cancer in a community oncology setting.","authors":"Amin Haiderali, Linda A Okoth, Srinivas Annavarapu, Jessica K Paulus, Wilbur Pan, Paul Conkling, Michael Danso","doi":"10.1080/14796694.2026.2693604","DOIUrl":"10.1080/14796694.2026.2693604","url":null,"abstract":"Background: Pembrolizumab, FDA-approved in July 2021, administered in combination with chemotherapy is the standard neoadjuvant treatment for high-risk, early-stage, triple-negative breast cancer (esTNBC) due to its efficacy in the KEYNOTE-522 trial. Identifying factors influencing clinical adoption is key to optimizing patient outcomes. This study explored physicians' perspectives on pembrolizumab use in the neoadjuvant and adjuvant settings, focusing on the treatment decision-making process for esTNBC.Methods: Eight US Oncology Network physicians (6 medical oncologists, 2 breast surgeons) participated in a survey and virtual focus group. Survey responses were analyzed descriptively, and focus group discussion transcripts underwent inductive thematic analysis.Results: Four themes emerged: widespread adoption of pembrolizumab as standard of care in esTNBC, rare nonuse due to contraindications, continued adjuvant use, and management of estrogen receptor (ER)-low/HER2- breast cancer similar to TNBC.Conclusions: The study highlights broad integration of pembrolizumab for esTNBC patients due to survival benefits and manageable safety profile. Nonuse was limited to contraindications, patient preferences, or due to surgery referrals without medical oncology input. To optimize patient outcomes, future efforts should focus on physician-patient communication, multidisciplinary care coordination, and surgeon education regarding neoadjuvant guidelines. Further guidance for optimal adjuvant treatment of patients without pathological complete response is necessary.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2067-2072"},"PeriodicalIF":3.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13456496/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148375542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognostic value of the lung immune prognostic index in metastatic gastric cancer: a single-center retrospective cohort study. 肺免疫预后指数在转移性胃癌中的预后价值：一项单中心回顾性队列研究

IF 3.1 4区医学

Future oncology Pub Date : 2026-07-01 Epub Date: 2026-07-17 DOI: 10.1080/14796694.2026.2704367

Savas Gokcek, Busra Kanbur, Ozge Yetginoglu, Ahmet Melih Arslan, Mehmet Uzun, Ilkay Tugba Unek

{"title":"Prognostic value of the lung immune prognostic index in metastatic gastric cancer: a single-center retrospective cohort study.","authors":"Savas Gokcek, Busra Kanbur, Ozge Yetginoglu, Ahmet Melih Arslan, Mehmet Uzun, Ilkay Tugba Unek","doi":"10.1080/14796694.2026.2704367","DOIUrl":"10.1080/14796694.2026.2704367","url":null,"abstract":"Aims: To evaluate the prognostic significance of the Lung Immune Prognostic Index (LIPI) in patients with metastatic gastric cancer (mGC).Patients and methods: We retrospectively analyzed 177 patients with mGC. Patients were stratified into three groups (good, intermediate, and poor) based on the LIPI score, which was calculated using a derived neutrophil-to-lymphocyte ratio (dNLR) >3 and lactate dehydrogenase (LDH) >upper limit of normal (ULN). Survival outcomes were analyzed using Kaplan-Meier and Cox regression models.Results: In univariate analyses, intermediate and poor LIPI, elevated dNLR and LDH, ECOG performance status ≥1, low albumin, and high CRP were significantly associated with overall survival. In multivariate analysis, poor LIPI remained an independent prognostic factor (HR: 3.43; 95% CI: 1.30-9.05; p = 0.013). ECOG performance status and C-reactive protein (CRP) were also independently associated with survival. Subgroup analysis showed a more pronounced prognostic impact of LIPI in Human Epidermal Growth Factor Receptor 2 (HER2)-negative patients.Conclusions: The LIPI is a simple, noninvasive, and inexpensive tool that provides strong prognostic information for patients with mGC, potentially aiding in better risk stratification in clinical practice.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2101-2108"},"PeriodicalIF":3.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13432856/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148470210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

How enzalutamide affects sex life and how taking a break from treatment affects quality of life: a plain language summary of results from the EMBARK study in people with hormone-sensitive prostate cancer and high-risk biochemical recurrence. 恩杂鲁胺如何影响性生活以及停止治疗如何影响生活质量：一篇对激素敏感性前列腺癌和高危生化复发患者进行的EMBARK研究结果的简明总结。

IF 3.1 4区医学

Future oncology Pub Date : 2026-07-01 Epub Date: 2026-07-05 DOI: 10.1080/14796694.2026.2691257

Stephen J Freedland, Ugo De Giorgi, Antti Rannikko, Fred Saad, Martin Gleave, Miguel Ramírez Backhaus, John Mulhall, Bhavik J Pandya, Jasmina Ivanova, Pavol Kral, James Turnbull, Neal Shore

引用次数: 0

Safety evaluation of epidermal growth factor receptor tyrosine kinase inhibitors in patients with interstitial pneumonia: a study using a Japanese nationwide database. 间质性肺炎患者表皮生长因子受体酪氨酸激酶抑制剂的安全性评价：一项使用日本全国数据库的研究

IF 3.1 4区医学

Future oncology Pub Date : 2026-07-01 Epub Date: 2026-06-17 DOI: 10.1080/14796694.2026.2690161

Yasutaka Ihara, Yukihiro Nakamura, Yuki Shimomura, Shoichiro Yamamoto

{"title":"Safety evaluation of epidermal growth factor receptor tyrosine kinase inhibitors in patients with interstitial pneumonia: a study using a Japanese nationwide database.","authors":"Yasutaka Ihara, Yukihiro Nakamura, Yuki Shimomura, Shoichiro Yamamoto","doi":"10.1080/14796694.2026.2690161","DOIUrl":"10.1080/14796694.2026.2690161","url":null,"abstract":"Introduction: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are standard first-line therapies for EGFR mutation-positive non-small cell lung cancer (NSCLC) but can cause rare, potentially fatal drug-induced interstitial lung disease (ILD). Patients with preexisting interstitial pneumonia (IP) are considered at increased risk; however, most prior studies excluded these patients, limiting real-world comparative evidence.Materials & methods: We identified patients with NSCLC who initiated first-line EGFR-TKI therapy between August 2018 and December 2024, using a nationwide Japanese claims database. Preexisting IP was defined using diagnosis codes combined with chest computed tomography records. Severe drug-induced ILD was defined as initiation of high-dose intravenous steroid pulse therapy. Cumulative incidence was estimated, and differences according to IP status were assessed using Fine-Gray models.Results: Among 13,092 eligible patients, 481 (3.7%) had preexisting IP. The 2-year cumulative incidence of severe drug-induced ILD was 3.2% in patients with IP and 1.7% in those without IP. Preexisting IP was associated with a higher risk of severe drug-induced ILD (subdistribution hazard ratio, 1.85; 95% confidence interval, 1.06-3.24).Conclusions: Preexisting IP was associated with an approximately twofold higher risk of severe drug-induced ILD during first-line EGFR-TKI therapy, supporting careful risk assessment and monitoring.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1975-1984"},"PeriodicalIF":3.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13580479/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148264227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world comparison of chemoimmunotherapy and chemotherapy alone in elderly patients (≥75 years) with extensive-stage small cell lung Cancer. 老年（≥75岁）广泛期小细胞肺癌患者化疗免疫治疗与单纯化疗的现实对比

IF 3.1 4区医学

Future oncology Pub Date : 2026-07-01 Epub Date: 2026-06-27 DOI: 10.1080/14796694.2026.2687697

Xue Dong, Wenjie Chen, Ruyue Li, Xiujing Yao, Yintao Li

{"title":"Real-world comparison of chemoimmunotherapy and chemotherapy alone in elderly patients (≥75 years) with extensive-stage small cell lung Cancer.","authors":"Xue Dong, Wenjie Chen, Ruyue Li, Xiujing Yao, Yintao Li","doi":"10.1080/14796694.2026.2687697","DOIUrl":"10.1080/14796694.2026.2687697","url":null,"abstract":"Introduction: Given the underrepresentation of adults aged ≥75 years with extensive-stage small-cell lung cancer (ES-SCLC) in clinical trials, we compared first-line chemoimmunotherapy versus chemotherapy in this population.Methods: This retrospective study enrolled 88 patients aged ≥75 years with ES-SCLC treated with either chemotherapy alone (n = 42) or chemoimmunotherapy (n = 46). The primary endpoint was overall survival (OS). Secondary endpoints included progression-free survival (PFS) and safety. Multivariable Cox regression and stabilized inverse probability of treatment weighting (IPTW) analyses were performed to reduce confounding.Results: Median OS and PFS were 14.3 (95% CI: 11.6-22.5) and 6.6 in the chemotherapy group and 16.9 (95% CI: 12.7-NA) and 7.6 months in the chemoimmunotherapy group, respectively (HR: 0.90, 95% CI: 0.51-1.58, p = 0.71; HR: 0.75, 95% CI: 0.43-1.29, p = 0.30, respectively). Multivariate analysis identified smoking status as an independent predictor of OS (HR: 2.10, 95% CI: 1.01-4.38, p = 0.048).Conclusion: Among patients aged ≥75 years with ES-SCLC, chemoimmunotherapy was associated with numerically longer OS compared with chemotherapy alone, although this difference did not reach statistical significance.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1955-1963"},"PeriodicalIF":3.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13390527/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148338426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0